Global Blood Therapeutics(GBT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GBT Global Blood Therapeutics

Halted 10-04 16:00:00 EDT

68.49

+0.00

0.00%

High68.49	Low68.49	Vol0.00
Open68.49	D1 Closing68.49	Amplitude0.00%
Mkt Cap4.62B	Tradable Cap4.01B	Total Shares67.48M
T/O224.61M	T/O Rate0.00%	Tradable Shares58.58M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GBT","market":"US","secType":"STK","nameCN":"Global Blood Therapeutics","latestPrice":68.49,"timestamp":1664913600000,"preClose":68.49,"halted":3,"volume":0,"delay":0,"floatShares":58576455,"shares":67476179,"eps":-5.001922,"marketStatus":"Halted","change":0,"latestTime":"10-04 16:00:00 EDT","open":68.49,"high":68.49,"low":68.49,"amount":224613300.78000003,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.001922,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766480400000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1439352000000,"exchange":"NASDAQ","adjPreClose":68.49,"volumeRatio":0},"requestUrl":"/m/hq/s/GBT","defaultTab":"news","newsList":[{"id":"2582675339","title":"Amex GBT Reports Strong Q3 Growth and Raises Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2582675339","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582675339?lang=en_us&edition=fundamental","pubTime":"2025-11-11 12:14","pubTimestamp":1762834460,"startTime":"0","endTime":"0","summary":"Global Business Travel Group, Inc. ( ($GBTG) ) has released its Q3 earnings. Here is a breakdown of the information Global Business Travel Group, I...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/amex-gbt-reports-strong-q3-growth-and-raises-guidance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/amex-gbt-reports-strong-q3-growth-and-raises-guidance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GBT"],"gpt_icon":0},{"id":"2572633123","title":"Amex GBT, SAP Concur to Launch Joint Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2572633123","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572633123?lang=en_us&edition=fundamental","pubTime":"2025-10-04 04:23","pubTimestamp":1759522980,"startTime":"0","endTime":"0","summary":"American Express Global Business Travel and SAP Concur are working together to launch Complete, a new service for booking, servicing, expensing and making payments on one platform.Complete will offer greater access to travel and expense data to improve spend management and access to more airline, hotel and rail content. Amex GBT, owned by Global Business Travel Group, is a software company focused on corporate travel, while SAP Concur helps companies manage employee travel expenses.Its services will be available on one app to make travelers' experiences simpler, with a single Amex GBT and SAP Concur team for customer service.Complete will also have AI-driven personalization and insights.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SAP","BK4585","BK4142","JYNT","BK4588","BK4139","GBT","GBTG","BK4613","BK4023","BK4528","BK4185"],"gpt_icon":0},{"id":"2571833367","title":"Press Release: Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2571833367","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571833367?lang=en_us&edition=fundamental","pubTime":"2025-09-29 20:15","pubTimestamp":1759148100,"startTime":"0","endTime":"0","summary":"NEW YORK, Sept. 29, 2025  -- Royalty Pharma plc  today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director. Dr. Love will continue to Chair the Nominating and Corporate Governance Committee.\"I am delighted to welcome Ted to the key role of Lead Independent Director,\" said Pablo Legorreta, Chief Executive Officer of Royalty Pharma and Chairman of the Board. \"Ted has extensive research-based biopharma experience gained over a long and successful career and currently serves as Immediate Past Chairman of the Biotechnology Innovation Organization's  Board of Directors. Ted has consistently demonstrated exceptional judgment and leadership, and we look forward to his continued stewardship as we advance our mission to accelerate innovation in life sciences.\". \"I am honored to be appointed Lead Independent Director,\" said Ted. \"Royalty Pharma's pioneering approach to life sciences inno","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999001176.SGD","IE00BLSP4239.USD","BK4581","IE000M9KFDE8.USD","SG9999001176.USD","LU0868494617.USD","IE00BBT3K403.USD","SG9999011175.SGD","SG9999002232.USD","GBT","LU1066051498.USD","BK4007","BK4585","LU0456855351.SGD","LU0985481810.HKD","IE00B19Z3B42.SGD","LU0225771236.USD","BK4568","IE0002270589.USD","BK4121","LU0321505439.SGD","BK4139","BK4599","SGXZ57979304.SGD","LU0321505868.SGD","RPRX","SG9999013999.USD","LU1066053197.SGD","SG9999002224.SGD","LU0289739699.SGD","LU1169589451.USD","LU1169590202.USD","LU0225284248.USD","LU1057294990.SGD","BK4533","BK4534","BK4588","LU1023059063.AUD","LU0058720904.USD","LU0234572021.USD","LU0170899867.USD","IE00B19Z3581.USD","LU0306806265.USD","LU1883839398.USD","LU0122379950.USD","BK4592","BIO","LU0306807586.USD","IE00BLSP4452.SGD"],"gpt_icon":1},{"id":"2569085567","title":"Press Release: Guerbet : H1 2025 results : H1 revenue: EUR387.8 million, down 5.4% at CER and on a like-for-like basis, mainly due to the decline in activity in France","url":"https://stock-news.laohu8.com/highlight/detail?id=2569085567","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569085567?lang=en_us&edition=fundamental","pubTime":"2025-09-24 23:45","pubTimestamp":1758728700,"startTime":"0","endTime":"0","summary":"-- H1 revenue: EUR387.8 million, down 5.4% at CER1 and on a like-for-like. basis2, mainly due to the decline in activity in France. By geographic region, the revenue of the EMEA region amounted to EUR169.6 million in the first half of 2025, down 7.7% at CER and like-for-like. Excluding France, revenue grew 6.9% at CER and like-for-like, driven by the increase in volumes.Sales in the Americas region were stable at CER and like-for-like , reflecting solid volume growth combined with price pressures resulting from the increased weight of distributors in the customer mix.In Asia, sales came to EUR98.6 million in the first half of the year, down 7.3% at CER and like-for-like, but the second quarter trended positively, up 1.2%. Performance was impacted by a significant delay in orders.By business activity, Diagnostic Imaging revenue stood at EUR334 million at mid-year, down 6.8% at CER and like-for-like.-- The sales of the IRM division  factor in. Interventional Imaging sales totaled EUR51.9","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4585","03160","BK4588","BK4232","FCF","BK4555","BK4139","GBT","R","BK4604","BK4211","TM","BK4099"],"gpt_icon":0},{"id":"2569736545","title":"Press Release: Guerbet : Change in General Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2569736545","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569736545?lang=en_us&edition=fundamental","pubTime":"2025-09-22 23:45","pubTimestamp":1758555900,"startTime":"0","endTime":"0","summary":"Villepinte France, September 22nd, 2025: Guerbet , a global specialist in contrast agents and solutions for medical imaging, announces the appointment of Mr. Jérme Estampes as interim Chief Executive Officer.Jérme Estampes replaces Mr. David Hale, who is leaving the Group to pursue new projects. The Board of Directors thanks him for his work since joining Guerbet in February 2018, initially as Chief Commercial Officer and then as Chief Executive Officer since January 1, 2020.Jérme Estampes has been with the Group since 2019 as Chief Administrative and Financial Officer, overseeing IT, business development, and licensing. In this role, he has gained an excellent understanding of the Group's current financial, operational, and commercial challenges.Supported by the Board of Directors, Jérme Estampes can rely on the support and experience of Guerbet's Executive Committee to ensure a smooth transition, continue implementing transformation measures, and deploy the Group's commercial strateg","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GBT","BK4139"],"gpt_icon":0},{"id":"2564802899","title":"Press Release: Amex GBT Completes Acquisition of CWT","url":"https://stock-news.laohu8.com/highlight/detail?id=2564802899","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564802899?lang=en_us&edition=fundamental","pubTime":"2025-09-02 20:10","pubTimestamp":1756815000,"startTime":"0","endTime":"0","summary":"--  Welcoming CWT customers to Amex GBT will unlock unrivaled choice, value. --  Transaction expected to create significant shareholder value with. approximately $155 million of annual run-rate identified synergies within. American Express Global Business Travel, which is operated by Global Business Travel Group, Inc.  , a leading software and services company for travel, expense and meetings & events, today announced that it has completed its acquisition of CWT, a global business travel and meetings solutions provider.The transaction, originally announced in March 2024, values CWT at approximately $540 million on a cash-free, debt-free basis, subject to certain assumptions and purchase price adjustments. With the close of the acquisition, Amex GBT welcomes CWT's customers and employees to its leading software solutions and services for travel, expense, meetings and events.CWT customers now gain access to Amex GBT's suite of proprietary travel and expense software solutions, including ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2106854487.HKD","LU1201861249.SGD","BK4585","GBTG","LU0942090050.USD","BK4139","LU2552382132.HKD","LU1778281490.HKD","LU0868494617.USD","LU0868494708.USD","CWT","AXP","LU2361044949.HKD","LU1861220207.SGD","LU0211327993.USD","IE00B7KXQ091.USD","LU0211328371.USD","LU1861217088.USD","LU2360107671.USD","LU2552382215.SGD","IE00BJJMRY28.SGD","BK4588","LU0980610538.SGD","LU1674673428.USD","BK4559","IE00BFSS8Q28.SGD","IE0004445015.USD","LU2023250504.SGD","IE0005OL40V9.USD","IE00B775H168.HKD","IE00BJJMRX11.SGD","LU2361045086.USD","GBT","LU0094547139.USD","LU2552382058.USD","LU1974910355.USD","LU0310799852.SGD","BK4142","IE00BSNM7G36.USD","LU1674673691.USD","LU1917777945.USD","BK4172","LU0130102774.USD","LU0011850046.USD","LU0648001328.SGD","LU1267930490.SGD","LU0266013472.USD","LU2461242641.AUD","LU2361044865.SGD","BK4598"],"gpt_icon":0},{"id":"2558650745","title":"Press Release: GBT Technologies Intends to Rebrand as Wertheim & Company; Craig Marshak Appointed CEO; Emil Assentato Joins as Strategic Investor","url":"https://stock-news.laohu8.com/highlight/detail?id=2558650745","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558650745?lang=en_us&edition=fundamental","pubTime":"2025-08-11 20:10","pubTimestamp":1754914200,"startTime":"0","endTime":"0","summary":"WEST HOLLYWOOD, Calif., Aug. 11, 2025  -- GBT Technologies Inc.   today announced its intention to change its corporate name to Wertheim & Company, subject to customary legal and regulatory approvals. The rebranding reflects the Company's plan to transition into a global merchant banking platform.Craig Marshak will be appointed Chief Executive Officer, bringing more than three decades of investment banking and growth capital experience, including his leadership role at Nomura's $500 million Growth and Technology Fund in London. Additionally, the Board of Directors intends to appoint Harinder Sandhu as a member.The \"Wertheim & Company\" trademark, which dates back to the original Wertheim & Company founded in 1927, has been registered by Mr. Marshak and is intended for adoption as part of the transition.There is no guarantee that any of the potential transactions described herein will be completed unless and until definitive agreements are signed.\"With this transition, GBT seeks to lever","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2286300806.USD","LU1861220033.SGD","LU1923622291.USD","LU2290526834.HKD","LU2491050071.SGD","LU0154245756.USD","BK4139","GBT","SG9999000418.SGD","BK4097","LU0107464264.USD","LU2125909759.SGD","LU2360107168.USD","LU2491050154.USD","LU2125909916.SGD","LU2065731478.USD","LU2491049909.HKD","LU0566484027.USD","CYBR","LU1169590202.USD","LU1559883803.SGD","LU1861215975.USD","GTCH","BK4134","LU0053671581.USD","LU1169589451.USD","BK4187","BK4560","VWAV","LU0154245673.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gbt.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing inclacumab, a novel human monoclonal antibody to treat vaso-occlusive crises; and GBT601, a hemoglobin polymerization inhibitor. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. The company was founded in 2011 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.043653},{"month":2,"riseRate":0.571429,"avgChangeRate":0.071249},{"month":3,"riseRate":0.571429,"avgChangeRate":0.017078},{"month":4,"riseRate":0.571429,"avgChangeRate":0.057551},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.003604},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.056299},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.018275},{"month":8,"riseRate":0.571429,"avgChangeRate":0.168625},{"month":9,"riseRate":0.5,"avgChangeRate":-0.021143},{"month":10,"riseRate":0.5,"avgChangeRate":0.056822},{"month":11,"riseRate":0.428571,"avgChangeRate":0.003345},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.011934}],"exchange":"NASDAQ","name":"Global Blood Therapeutics","nameEN":"Global Blood Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Global Blood Therapeutics(GBT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Global Blood Therapeutics(GBT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Global Blood Therapeutics,GBT,Global Blood Therapeutics股票,Global Blood Therapeutics股票老虎,Global Blood Therapeutics股票老虎国际,Global Blood Therapeutics行情,Global Blood Therapeutics股票行情,Global Blood Therapeutics股价,Global Blood Therapeutics股市,Global Blood Therapeutics股票价格,Global Blood Therapeutics股票交易,Global Blood Therapeutics股票购买,Global Blood Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Global Blood Therapeutics(GBT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Global Blood Therapeutics(GBT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}